article thumbnail

Building Azure DevOps CD Processes for SPFx

Perficient: Drug Development

Continuous Deployment (CD) takes validated code packages from the build process and deploys them into a staging or production environment. Developers can track successful deployments and narrow issues to specific package versions. From the left navigation, click Pipelines > Releases. Name your environment. Search for Node.

article thumbnail

Tutorial 4 – Microservices – Discovery Client, LoadBalancer Client and Feign Client.

Perficient: Drug Development

Feign Client It is termed abstract client because we just supply an interface with method definition and annotation. So, other instances of the target may sit idle. To solve these problems, use the “ LoadBalancerClient ” type client component. return new ResponseEntity<String>("Final billAmount = billAmount - discount (RS.

Packaging 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Product Highlight: DrugBank Data Dictionary

DrugBank

Your Definitive Source of Truth The Data Dictionary is tailored to transform your data experience, offering the official DrugBank perspective on every piece of information in our database. Enhanced User Experience By offering immediate access to detailed data definitions, the Data Dictionary saves you time and reduces errors.

article thumbnail

Article Periodic Thank You Commission unveils “one substance, one assessment” reform package

Agency IQ

Commission unveils “one substance, one assessment” reform package The Commission has long aspired to realize its one substance, one assessment concept in the EU’s chemical regulatory regime. Analysis One wonders what role the envisioned ECHA basic regulation will have in supporting this reform package.

article thumbnail

FDA Issues Long-Awaited QMSR Final Rule

FDA Law Blog: Biosimilars

Both ISO 13485 and ISO 9000 contain terms and definitions that are referenced within Part 820. FDA further retained some definitions in the QSMR. FDA further retained some definitions in the QSMR. Certain definitions are also removed from § 820.3, Revised § 820.3

FDA 59
article thumbnail

Article EMA Thank You New guidance provides definition for orphan device, offers alternative trial designs

Agency IQ

New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. Does this guidance offer the formal definition of “orphan device” we’ve been waiting for?

Trials 40
article thumbnail

ChEMBL 34 is out!

The ChEMBL-og

A significant effort has been made to correctly map the drug form of the EMA data by manually inspecting different EMA sources of information, such as the Product Information (Annex I: Summary of Product Characteristics and Annex III: Labelling and Package Leaflet) and/or Assessment Report, where available. University of Dundee: T.